2.36 USD
-0.35 (-12.75%)
At close: Jun 18, 2025
1.8001 USD
-0.56 (-23.72%)
After Hours: 6/18/2025, 8:03:30 PM
Taking everything into account, LIPO scores 2 out of 10 in our fundamental rating. LIPO was compared to 525 industry peers in the Biotechnology industry. While LIPO has a great health rating, there are worries on its profitability. LIPO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year LIPO has reported negative net income.
- In the past year LIPO has reported a negative cash flow from operations.
- LIPO had negative earnings in each of the past 5 years.
- In the past 5 years LIPO always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -105.66%, LIPO is doing worse than 77.78% of the companies in the same industry.
- LIPO has a Return On Equity (-125.78%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.66% | ||
| ROE | -125.78% | ||
| ROIC | N/A |
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for LIPO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, LIPO has more shares outstanding
- The number of shares outstanding for LIPO has been reduced compared to 5 years ago.
- There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of 0.93, we must say that LIPO is in the distress zone and has some risk of bankruptcy.
- LIPO's Altman-Z score of 0.93 is fine compared to the rest of the industry. LIPO outperforms 65.59% of its industry peers.
- There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.93 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
- A Current Ratio of 6.21 indicates that LIPO has no problem at all paying its short term obligations.
- LIPO's Current ratio of 6.21 is fine compared to the rest of the industry. LIPO outperforms 62.01% of its industry peers.
- A Quick Ratio of 6.21 indicates that LIPO has no problem at all paying its short term obligations.
- LIPO's Quick ratio of 6.21 is fine compared to the rest of the industry. LIPO outperforms 62.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.21 | ||
| Quick Ratio | 6.21 |
3. Growth
3.1 Past
- LIPO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.74%.
- LIPO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.88%.
- Measured over the past years, LIPO shows a decrease in Revenue. The Revenue has been decreasing by -5.04% on average per year.
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%
3.2 Future
- The Earnings Per Share is expected to grow by 19.87% on average over the next years. This is quite good.
- Based on estimates for the next years, LIPO will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LIPO. In the last year negative earnings were reported.
- Also next year LIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- LIPO's earnings are expected to grow with 19.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
5. Dividend
5.1 Amount
- No dividends for LIPO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIPELLA PHARMACEUTICALS INC / LIPO FAQ
What is the fundamental rating for LIPO stock?
ChartMill assigns a fundamental rating of 2 / 10 to LIPO.
Can you provide the valuation status for LIPELLA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 0 / 10 to LIPELLA PHARMACEUTICALS INC (LIPO). This can be considered as Overvalued.
Can you provide the profitability details for LIPELLA PHARMACEUTICALS INC?
LIPELLA PHARMACEUTICALS INC (LIPO) has a profitability rating of 0 / 10.
How financially healthy is LIPELLA PHARMACEUTICALS INC?
The financial health rating of LIPELLA PHARMACEUTICALS INC (LIPO) is 7 / 10.